MedTrace Logo

Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors

NCT01074320 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2015-12-16

No results posted yet for this study

Summary

Current guidelines recommend endocrine treatment with aromatase inhibitors (AIs) in post-menopausal women with hormone receptor-positive breast cancer. Musculoskeletal symptoms are commonly reported with AI treatment,however, we do not have consistent methods to measure these symptoms prospectively. This gap in our knowledge inhibits the ability to test and develop treatments for AI-associated musculoskeletal symptoms. This pilot study will evaluate functional tests and standardized instruments for their ability to prospectively assess musculoskeletal symptoms in women being treated with AIs for breast cancer.

Conditions

Interventions

OTHER

Other

Observational study

Sponsors & Collaborators

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Karen K Swenson, RN, PhD · HealthPartners Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01074320 on ClinicalTrials.gov